Alinidine

Alinidine
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.164.275
Chemical and physical data
FormulaC12H13Cl2N3
Molar mass270.16 g·mol−1
3D model (JSmol)
SMILES
  • Clc2cccc(Cl)c2N(/C1=N/CCN1)C\C=C
InChI
  • InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16) checkY
  • Key:OXTYVEUAQHPPMV-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]

References

  1. ^ Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 1987, 410:83-91
  2. ^ Current Opinion in Pharmacology 2007, 7:208–213
  3. ^ Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy". J Am Coll Cardiol. 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.